Skip to main content

Effective #treatment of advanced #Oropouche virus, Rift Valley fever virus, and Dabie #bandavirus #infections with 4'-fluorouridine

Image
By G.M.

 


ABSTRACT

Oropouche virus (OROV), Rift Valley fever virus (RVFV), and Dabie bandavirus (DBV) are significant re-emerging and emerging human pathogens with major public health implications. Notably, the ongoing OROV disease epidemic spanning South America, Central America, and the Caribbean now exceeds 11,000 cases, including several fatalities and reports of neurological disease and congenital abnormalities associated with infection. Rift Valley fever outbreaks continue to plague sub-Saharan Africa, and DBV, the etiologic agent of severe fever with thrombocytopenia syndrome (SFTS), is expanding its reach throughout several Asian countries. No vaccines or approved therapies are available to prevent or treat these viral infections. Here, we report on the antiviral activity and protective efficacy of the ribonucleoside analog, 4′-fluorouridine (4′-FlU), against OROV, RVFV, and DBV in cell culture and murine models of infection and disease. In cell culture, the potency of 4′-FlU was in the low nanomolar (OROV) to low micromolar (RVFV and DBV) range. In vivo, prophylactic oral dosing of the compound was fully protective against all three viruses in their respective mouse infection models. Importantly, post-exposure and therapeutic interventions of advanced infections in mice also responded remarkably well to treatments. Our findings extend the broad-spectrum antiviral capacity of 4′-FlU and support the compound’s further development for treating severe bunyaviral infections.


IMPORTANCE

Re-emerging and emerging viral diseases, for which no approved vaccines or therapeutics exist, pose a significant public health threat in affected areas of the world. Antiviral drugs that are broadly active against multiple pathogenic viruses are much needed. Our findings demonstrating robust protection conferred by treatment with 4′-fluorouridine (4′-FlU) in viral infection models for Oropouche fever, Rift Valley fever, and severe fever with thrombocytopenia syndrome support the continuing development of this promising broad-spectrum antiviral drug candidate for the treatment of these notable viral diseases.

Source: mBio, https://journals.asm.org/doi/full/10.1128/mbio.01467-25?af=R

____

Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »